{"filing":{"accession_number":"0001437749-26-021832","cik":"0001645469","ticker":"MNPR","company_name":"Monopar Therapeutics","form":"8-K","filing_date":"2026-06-26","report_date":null,"primary_document":"mnpr20260625_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926021832/mnpr20260625_8k.htm"},"events":[{"id":14222,"run_id":12650,"accession_number":"0001437749-26-021832","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Monopar announced new Phase 3 clinical trial analyses for ALXN1840 showing superior neurologic and global clinical benefit versus standard of care in Wilson disease patients, to be presented at the European Academy of Neurology Congress. This disclosure of positive clinical trial data supporting a planned NDA submission is a material operational/clinical milestone for a clinical-stage biopharmaceutical company, but does not fit the specific categories of earnings_release (no financial results), exec_appointment/departure, or ma_activity. The event is clearly operational in nature—a significant clinical development milestone—making operational_other the most appropriate classification.","company_name":"Monopar Therapeutics","ticker":"MNPR","filing_date":"2026-06-26","form":"8-K","submitted_at":null,"items":[{"id":11590,"accession_number":"0001437749-26-021832","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Monopar announced new Phase 3 clinical trial analyses for ALXN1840 showing superior neurologic and global clinical benefit versus standard of care in Wilson disease patients, to be presented at the European Academy of Neurology Congress. This disclosure of positive clinical trial data supporting a planned NDA submission is a material operational/clinical milestone for a clinical-stage biopharmaceutical company, but does not fit the specific categories of earnings_release (no financial results), exec_appointment/departure, or ma_activity. The event is clearly operational in nature—a significant clinical development milestone—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:10:21.530910+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11590,"accession_number":"0001437749-26-021832","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Monopar announced new Phase 3 clinical trial analyses for ALXN1840 showing superior neurologic and global clinical benefit versus standard of care in Wilson disease patients, to be presented at the European Academy of Neurology Congress. This disclosure of positive clinical trial data supporting a planned NDA submission is a material operational/clinical milestone for a clinical-stage biopharmaceutical company, but does not fit the specific categories of earnings_release (no financial results), exec_appointment/departure, or ma_activity. The event is clearly operational in nature—a significant clinical development milestone—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:10:21.530910+00:00","company_name":"Monopar Therapeutics","ticker":"MNPR","filing_date":"2026-06-26"}]}